Navigation Links
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Date:10/15/2007

een approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc.

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led by Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS-760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
5. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
6. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Point of Care Strep Tests Speed Treatment, Lower Costs
10. Rapid HIV Testing Increases Possibility of Treatment
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  ResMed Inc. (NYSE: RMD ) ... fiscal year ended June 30, 2014.  Revenue for the quarter ... 30, 2013 (a 1 percent decrease on a constant currency ... percent compared to the quarter ended June 30, 2013. Diluted ... of 22 percent compared to the quarter ended June 30, ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Conference, New York, NY Wednesday, August ... Baird Health Care Conference, New York, NY ... , Accessing Live Webcasts To access the live ...
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
(Date:8/1/2014)... Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and transgender ... the same problems as some of their heterosexual and ... they often face additional physiological and legal challenges ... recent advances in assisted reproduction options is presented in ... Future Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Market ... research reports have been added to its catalogue. ... Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing ... key pharma industry drivers include, among others, increasing ... personal hygiene. In 2015, the pharma market in ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The North ... endpoint security solutions market in North America with analysis ... grow from around $3.53 billion in 2014 to $4.77 ... 2014 to 2019. , Browse through the TOC of ... an idea of the in-depth analysis provided. It also ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:FDA Approves New Treatment for People With COPD 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... promote cancer screening by announcing that only one in five ... to have an examination. But a new study published in ... Psychological Science, finds that this well-meaning message has the exact ... get screened. In an earlier study, Monika Sieverding ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) ... the clot-dissolving drug tPA from 3 hours to up to ... any significant delays in treatment and appears to be a ... there was a slight increased risk of death and bleeding ...
... , MONDAY, July 26 (HealthDay News) -- Too many ... prostate-specific antigen (PSA) is normal or below normal, still ... evidence has shown that among older men with low-risk ... but another condition. For these men, watchful waiting is ...
... studies that compares two treatments for preventing strokes due carotid artery ... UT Southwestern Medical Center physician reports in an editorial in today,s ... "The most recent data on treatment options for carotid artery disease ... Dr. Ethan Halm, chief of the William T. and Gay F. ...
... Reporter , MONDAY, July 26 (HealthDay News) -- Doctors across ... open up clogged neck arteries to help prevent stroke, a ... fills up major arteries supplying blood to the brain, greatly ... the condition: an artery-scraping surgery called endarterectomy; the placement of ...
... cancer survival is associated with increased risk of long-term ... the July 26 issue of Archives of Internal ... to background in the article, childhood cancer survival rates ... roughly 70 to 80 percent currently. The authors also ...
Cached Medicine News:Health News:Few people are doing it, so why should I? Motivating men to seek cancer screening 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 3Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 3Health News:Surgery or stenting for carotid artery disease? Question remains 2Health News:Surgery or stenting for carotid artery disease? Question remains 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 2Health News:Stroke Prevention Treatment Varies Widely Across U.S. 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 4Health News:Childhood cancer survivors may have abnormal long-term cardiac function 2
... can be difficult for persons who have ... cord injuries and for children with poor ... other motor or coordination problems. The FoamWrap ... and coordination. Soft foam-lined material provides light ...
... a low profile contour at the palmar crease ... is an excellent choice to treat mild to ... or for wear following cast removal. The ... pile cinch fasteners provides support and compression to ...
... to treat DeQuervain's Tendonitis, strains and sprains ... advanced carpal tunnel syndrome and cumulative trauma ... Distal palmar crease contour allows for 90 ... Constructed from an open cell urethane ...
... is a solid, one-piece custom wrist orthotic designed to ... , ,Indications: , Wrist reconstruction , ... , Coles fracture - distal radius , ... , ORIF - Open reduction and internal ...
Medicine Products: